SAN DIEGO, Feb. 3, 2014 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced the initiation of dosing in a clinical trial evaluating the combination of TRC105 and Votrient® (pazopanib, GlaxoSmithKline), a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, to treat patients with advanced soft tissue sarcoma. TRC105, a novel monoclonal antibody to endoglin (CD105), is being studied in multiple clinical trials in combination with agents that target the VEGF pathway.
Help employers find you! Check out all the jobs and post your resume.
